Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiotherapy Better than Surgery for Some Lung Cancer Patients

By HospiMedica staff writers
Posted on 09 Apr 2007
After an initial chemotherapy treatment, radiation may be a better choice than surgery for patients with stage IIIA non-small-cell lung cancer, according to new research.

Findings from the randomized controlled trial were published in the March 21, 2007, issue of the [U.S.] Journal of the National Cancer Institute. More...
The researchers who performed the study suggest that a combination of chemotherapy and radiation should be the preferred treatment option for these patients.

About 80% of all lung cancers are non-small-cell lung cancers (NSCLCs), and of those patients diagnosed with NSCLC, approximately 30% have locally advanced stages IIIA or IIIB. Earlier research had shown that treating stage IIIA patients with chemotherapy before surgery increases the survival rate compared with patients receiving only surgery. The researchers had originally theorized that surgery would be more effective than radiation after chemotherapy treatment.

Jan van Meerbeeck, M.D., Ph.D., from the University Hospital of Ghent (Belgium) and colleagues from the European Organization for Research and Treatment of Cancer (EORTC) recruited 579 eligible patients from 41 institutions into the trial between December 1994 and December 2002. All of the patients were diagnosed with stage IIIA-N2 NSCLC that had progressed so far that it could not be completely removed by surgery.

The patients were first given three cycles of platinum-based chemotherapy. Those who responded to the treatment--61% of the initial group--were then randomly assigned to receive surgery or radiation, 167 and 165 patients, respectively.

The investigators discovered that surgery, compared to radiation, did not improve survival after treatment with chemotherapy. The median survival time for surgical patients was 16.4 months vs 17.5 months for patients who were treated with radiation. The five-year overall survival rate for surgical patients was 15.7%, compared with 14% for patients who received radiation. Although the survival rates for the two groups were very similar, the researchers concluded that radiation was the preferred treatment because of its lower rate of complications and mortality in lung cancer patients.

"These results are important because several centers routinely use…chemotherapy followed by surgery to treat patients with this stage of disease based on small randomized studies that showed that surgery alone is inferior to…chemotherapy and surgery in stage IIIA patients,” the authors wrote in their article.


Related Links:
University Hospital of Ghent

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.